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Extract
Twenty-four jaundiced neonates were studied, 12 in the treatment group and 12 in the untreated group. Patients were randomly selected to receive oral riboflavin. The mean 24-hr bilirubin decrease was determined during phototherapy. Blue light (420-470 nn) energy ranged fran 6-10 pW/cmZ. The observed 24-hr bilirubin decrease was compared with the expected decrease based on an energy-dose-response relationship. Riboflavin-treated infants received either 6-7 pW/cm2 blue light energy or 8-10 pW/cm2 (same as control group). Those infants receiving less energy than the control group (8-10 pW/cm2) had a mean 24-hr bilirubin decrease (3.05 mg/100 m1/24 hr) equal to the control group (3.09 mg/100 m1/24 hr). Those riboflavin-treated infants receiving energy equal to the control group showed a greater decline (5.2 mg/100 m1/24 hr) in their mean 24-hr bilirubin. Although effective, additional in vivo studies are required to clarify the full effects, especially on DNA, of using photosensitizers such as riboflavin in the presence of bilirubin and blue light energy (420-470 nm).
Speculation
Riboflavin may becane an inportant adjunct to phototherapy for neonatal hyperbilirubinemia. As a producer of singlet oxygen it is capable of transferring enough energy to overcane the oxygen quenching effect of bilirubin in its rapid degradation.
Riboflavin (6',7-dimethyl-9-(D-If-ribityl) isoalloxazine is an essential dietary constituent for mammals (9) . The mono-or dinucleotide form functions as the prosthetic group of a number of important enzymes. Flavin mononucleotide, riboflavin 5'-phosphate is formed from riboflavin and ATP catalyzed by flavokinase. Further addition of ATP with the mononucleotide forms PP, and FAD, an important nucleotide and coenzyme in cellular respiration. All biologic functions of riboflavin appear to be limited to its contribution to the synthesis of these two coenzymes. In man, ingested riboflavin is excreted largely unchanged or as riboflavin 5'-phosphate (FMN).
Recent in vitro (7) and in vivo (4) evidence indicates that riboflavin enhances the photodecomposition of bilirubin. Application of this principle to phototherapy for neonatal hyperbilirubinemia using blue light energy in a predictable doseresponse relationship (5) forms the basis for this report.
MATERIALS AND METHODS
All infants studied were at term (38-40 weeks) and predominantly Caucasian. Assignment to the study was made only after the infants were committed to phototherapy for hyperbilirubinemia by their private pediatricians (10) .
Study subjects included 24 infants born at St. Francis Hospital, Tulsa, Oklahoma. There were 12 males and 12 females. Hyperbilirubinemia was defined as a serum bilirubin concentration greater than 9 mg/100 ml and phototherapy was initiated at or above this level (range 9-18 mg/100 ml). Blue light energy was administered and measured as described in a previous report (5) .
Serum bilirubin was collected and measured. All infants studied had developmental (physiologic) jaundice with no laboratory or clinical evidence of illness or hemolytic process. A system of random numerical selection was used to determine which patients were to receive riboflavin. The treated group received oral deker (4, 7) suggested that riboflavin may be an important adjunct riboflavin as the sodium phosphate (10) 1.5 mg/kg every 12 hr. to phototherapy in lowering serum bilirubin levels in newborn Riboflavin therapy was begun 6 hr before phototherapy and was infants. They suggested that riboflavin, a sensitizer, absorbs light discontinued after the first 24 hr of light treatment. Both treated energy in the presence of oxygen and becomes excited to a higher and control groups were fed a prepared formula (20 cal/oz) every energy state (triplet form). This energy in the form of singlet 3-4 hr. The mean riboflavin per 24 hr administered in the formula oxygen is then transferred to bilirubin, also a sensitizer, which then was calculated as 0.3 mg/infant. reacts with the singlet oxygen to undergo photodecomposition. During the course of the study presented herein, two important papers came to our attention. One of these (8) reported that RESULTS riboflavin in the presence of light altered one of the base moieties Table 1 describes the characteristics of the patients in the three of purified DNA with minimal cleavage of the phosphodiester study groups. One-half of the riboflavin-treated infants received linkages. A similar effect was noted in living human HeLa cells. approximately 50% less blue light irradiance (5) than the control The authors suggested that such mutational changes in the DNA group and yet had a similar mean 24-hr bilirubin decrease. On the structure could occur which may have carcinogenic potential. other hand, the riboflavin-treated group that received irradiance Speck's group (8), however, did not study the effects on DNA of equal to that of the control group had a 2.1 mg/100 ml greater riboflavin and phototherapy in the presence of bilirubin. Meanreduction in serum bilirubin over a similar time period.
while, Foote et al. (2) studied the kinetics of bilirubin photo-oxidaThe observed mean 24-hr bilirubin decrease for all three study tion in relation to singlet oxygen. They concluded that although groups was plotted against the predicted 24-hr decrease based on bilirubin quenched singlet oxygen faster than it reacted with it, it the time-dose response curve (5) (Fig. 1) . The control group results was still one of the most reactive known receptors of singlet were as predicted.
oxygen. They also observed that riboflavin was a very potent N o recognizable complications resulted from this study.
sensitizer, thus generating considerable singlet oxygen when exposed to light. They suggested that since riboflavin did not react and thus photodegrade, it could surely result in severe tissue DISCUSSION photodynamic damage. Riboflavin metabolism in the newborn infant has received very Riboflavin being the "super" sensitizer, it might be expected to little attention (I, 3), particularly in regard to the association of generate singlet oxygen at a rate greater than bilirubin was able to riboflavin and phototherapy. Recently Kostenbauder and Sanvor-quench, thus accounting for a greater reactive phenomenon and greater photodegradation. Likewise, it would seem plausible to expect less singlet oxygen attack on DNA structure if indeed the In view of the recent in vitro observations on the effect of phototherapy on DNA in the presence of riboflavin, however, we ' Characteristics of light measuring device: peak sensitivity 460 nm; cannot recommend its use during phototherapy. We urge further in half-maximal sensitivities 385 and 507 nm.
vitro and animal study to ascertain the safety of using riboflavin as Decrease observed during the first 24 hr of phototherapy.
an adjunct to phototherapy in human infants. The influence riboflavin had on bilirubin response to phototherapy was studied in 24 newborn infants, 12 in the treated group and 12 in the untreated group. Those patients receiving riboflavin showed a 50% greater mean bilirubin decrease during the first 24 hr of phototherapy when compared to patients receiving no riboflavin, but the same quantum of blue light energy. Dr. Smith, members of the Smith family, friends of Dr. Smith, and admirers-that must include everyone in this roomSurely one of the greatest pleasures that can befall a "student" is the opportunity to share with others perceptions of a favorite "teacher" (Fig. I) . This pleasure is mine today, as I attempt to bring you some feeling for Clement Smith and his extraordinary accomplishments.
Introduction of
To many he conveys the wisdom of the lover of nature, and seems more a Vermonter (his adopted land) than the midwesterner he is. The medical years began in Ann Arbor, where he received his M.D. from the University of Michigan in 1928. His first 2 years as a house officer were in the University Hospital in Ann Arbor, but in 1931 he came to the Children's Hospital, Boston, in the era of Drs. Kenneth Blackfan, James Gamble, and James Wilson. Any of you who have had the privilege of knowing Dr. Smith realize the extent to which the friendships of those years have influenced his subsequent life. One sometimes wonders if the Children's Hospital ever had a Chief Resident other than James Wilson. Dr. Smith returned to Ann Arbor as Instructor in Pediatrics but only briefly, when Harvard again beckoned him to come in the role of Assistant Physician to the Children's Hospital. He was at first in charge of the Tuberculosis Clinic and an Attending Physician, but his eyes roamed across the street on occasion to the Lying-In, where he became particularly fascinated by the problems of young infants. In 1937 Dr. Stewart Clifford invited him to take a more major role
